Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSV: LOVE )

1.400 +0.020 (+1.45%)
Streaming Delayed Price Updated: 3:51 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 51,108
Open 1.350
Bid (Size) 1.390 (10)
Ask (Size) 1.400 (46)
Prev. Close 1.380
Today's Range 1.350 - 1.400
52wk Range 0.5200 - 1.460
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire

Performance

YTD
+75.00%
+75.00%
1 Month
+5.26%
+5.26%
3 Month
+64.71%
+64.71%
6 Month
+108.96%
+108.96%
1 Year
+64.71%
+64.71%

More News

Read More
Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Canadian Cannabis Producer Cannara Reports 43% YoY Revenue Growth, Boosts Market Share And Profitability
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports Q3 2024 Financial Results
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss
Via Benzinga
Topics Cannabis
Exposures Cannabis
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.